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Abstract
Impaired endothelial function and microvascular dysfunction are frequently observed in
individuals with cardiovascular risk factors such as obesity, insulin resistance, and type 2
diabetes. Reduced nitric oxide (NO) bioavailability is considered to be central to the
development of these risk factors. NO can be generated via enzymatic reaction via NO synthase
which requires the amino acid arginine. Evidence suggests that the amino acid citrulline is more
effective at increasing circulating arginine levels than arginine supplementation alone. The
purpose of this pilot study is to determine the potential for citrulline-rich watermelon juice
(WMJ) to attenuate the reduction in postprandial endothelial function associated with reduced
skeletal muscle microvascular blood flow (MVBF) during hyperglycemia. Seventeen (12
female) non-obese (%Fat Mass= 27.72±7.89%) young adults (Age= 23±3y), with normal or
overweight BMI (BMI= 23.48±3.22kg/m2) were enrolled in this study. In a randomized,
crossover, double-blinded design, participants supplemented with WMJ or placebo (PLA)
(average 12.8, 10-16 days) then underwent an oral glucose tolerance test (OGTT) after an
overnight fast. Flow-mediated dilation (FMD) was greater after WMJ compared to PLA
following the oral glucose challenge (treatment p=0.038). Baseline oxygen saturation (StO2)
was significantly higher in WMJ vs PLA (p=0.031) and the baseline StO2 area under the curve
(AUC) was significantly greater in WMJ vs PLA (p=0.03). Our findings suggest that WMJ
supplementation is a potentially effective method for improving vascular responsiveness during
hyperglycemia via improved skeletal muscle tissue oxygen saturation and improved resting
endothelial function.
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Chapter 1. Literature Review
1.1 Introduction
17.9 million people die each year from cardiovascular disease (CVD) which accounts for
31% of deaths worldwide with the majority of these coming from a heart attack and stroke [20].
Cardiovascular disorders are related to the heart and vessels and include coronary heart disease
and rheumatic heart disease. Individuals with CVD have a higher likelihood of other risk factors
such as endothelial dysfunction, hypertension, atherosclerosis, insulin resistance, obesity, and
type 2 diabetes (T2D). These diseases and risk factors have strong vascular and endothelial
components if improved could improve quality of life and reduce the frequency of premature
death. CVD and many of the related diseases are known or suspected to be related to diminished
arginine and nitric oxide (NO) bioavailability which contribute to vascular and endothelial
dysfunction [33].
The vascular and endothelial systems work in conjunction as a network of vessels and
muscles throughout the entire body. The vascular system is responsible for distributing blood
and nutrients throughout the body to all of the tissues. The endothelium acts as a regulator as
well as a barrier between the blood and other tissues of the body. Blood flow is largely affected
by the vascular tone which can be vasodilated or vasoconstricted to change the amount of blood
flow to an area. Vascular tone is altered by endothelium-derived or non-endothelium derived
vasodilation or vasoconstriction.
Non-endothelium dependent changes in vascular tone are regulated by the autonomic
nervous system. Individuals’ sympathetic response to extrinsic stimuli such as stress, danger, or
pain directly elevating vascular resistance [39]. The endothelium is innervated with neural
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transmitters from the autonomic nervous system signals the change in vascular tone.
Neurotransmitters including norepinephrine and acetylcholine can act on the endothelium and
counteract endothelial-dependent changes in the vasculature. Norepinephrine when bound to the
α2-adrenergic receptors on the endothelium counteract the endothelium-dependent vasodilation
and induce vasoconstriction of the endothelium smooth muscle cells [39]. Acetylcholine can
mediate vasorelaxation by regulating NO release, but it can also inhibit NO production if
activated on the M2 and M3 receptors [39]. Conversely, endothelium-dependent changes are
mediated by the bioavailability of NO.
Diminished NO bioavailability is considered to play a role in nearly all cardiometabolic
disease states. Patients with T2DM are at increased risk for developing mico- and macrovascular
dysfunction which contributes to the increased risk of CVD in this group. This review will focus
on the effects of hyperglycemia on vascular and endothelial function as well as a possible
solution by increasing the bioavailability of NO. Citrulline has shown promising effects on NO
bioavailability that could dampen the effects of cardiometabolic disease on the vascular and
endothelial systems.
1.2 Nitric Oxide
Discovered in 1987, NO is a vasoprotective molecule that is synthesized by endothelial
nitric oxide synthase (eNOS) which can be a major component to fighting cardiovascular disease
[21]. NO is responsible for changing the tone of the vasculature regulating hemodynamics of the
associated tissues. Endothelium-derived NO is synthesized from the amino acid L-arginine by
eNOS, yielding L-citrulline as a byproduct [2]. After NO is synthesized, NO diffuses across the
endothelial cell membrane, entering the vascular muscle cells where soluble guanylate cyclase
(sGC) is activated leading to an increase in cyclic guanosine monophosphate (cGMP) synthesis
2

[4]. cGMP acts as a secondary messenger that controls the vascular tone and platelet function by
mediating the effects of NO [4]. This process makes NO a potent vasodilator while also
suppressing platelet aggregation, leukocyte migration and cellular adhesion to the endothelium,
and attenuates vascular smooth muscle cell proliferation and migration [22].
Nitric oxide undergoes rapid oxidation to form nitrite, and further oxidation into nitrate.
Conversely, NO can be generated the reduction of nitrate and nitrite by a series of biological
reactions in the body (25, 26). This reaction along with oral ingestion are the two main sources
of nitrate/nitrites in human metabolism [24]. Once ingested, foods naturally high in nitrates such
as beetroot, spinach, and celery are broken down by the saliva and reduced from nitrate to nitrite
and are absorbed through the gastrointestinal tract entering circulation [23]. Nitrite is then
reduced to NO in the cells and tissues by several proteins and enzymes [24]. Carlstrom et al
(2015) suggests that higher chronic doses of nitrates could be detrimental to endothelial function
by increasing the formation of reactive nitrogen oxides as well as decreasing the amount of sGC
while smaller and acute doses are beneficial [23].
1.3 Citrulline
Citrulline is a non-essential amino acid that has been shown to increase the
bioavailability of NO production by increasing the bioavailability of arginine, a precursor to NO.
Citrulline is also an important component in the urea cycle in the liver and kidneys [6]. While
being mainly used in NO production, citrulline has been used as a biomarker for functional small
bowel enterocyte mass due to being almost exclusively synthesized in the small intestine [31]. In
addition, increased plasma citrulline has been noted as a potential marker for renal function due
to the kidneys being the main site of citrulline conversion to arginine [32]. Citrulline is typically
supplemented by watermelon juice, watermelon extract, pharmaceutical grade citrulline, or
3

citrulline conjugated with malate (1:1 ratio) [30]. The main food source of citrulline is
watermelon, particularly the rind and seeds have the highest concentrations, with 1.6-3.5 g/kg of
citrulline per whole watermelon [1]. Citrulline is effective at doses as low as 1g/day and as high
as 10g/day with no known toxicity [1, 50]. With the possible endothelial benefits, watermelon
products (juice, extract, etc.) should be considered as a natural, relatively cost-effective
alternative to pharmaceutical-grade citrulline.
The oxidative production of NO and citrulline requires the three main nitric oxide
synthase enzymes (eNOS, iNOS, and nNOS) [6]. Arginine is hydrolyzed yielding NO and
citrulline. Citrulline is then sustained in the endothelial cells yielding more arginine to create
NO [7]. Citrulline is coproduced with NO as an end product of NOS activity, which can be then
be recycled into arginine for additional NO production in this citrulline- NO cycle [16]. When
ingested, approximately 40% of arginine is catabolized by intestinal bacteria then passes through
the liver where arginase breaks down arginine yielding urea and ornithine accounting for another
10-15% extraction [3, 15]. Unlike arginine, citrulline is not acted on by first-pass extraction in
the liver by arginase enzyme allowing for citrulline to be converted to argininosuccinate and
subsequently arginine in the kidneys by argininosuccinate lyase [55]. This process yields more
circulating arginine allowing eNOS to produce NO.
NO is an integral part of endothelial physiology, leading to increased vasodilation,
therefore improving blood pressure and serum cholesterol along with several other factors.
Citrulline can be converted to arginine in the kidneys, bypassing the uptake of the liver allowing
for an increase in NO downstream. Conversely, ingested arginine will be taken up by the liver,
and converted into urea and ornithine, thereby diminishing the amount of arginine that can be
used to create NO.
4

1.4 Vasoprotective effects
Individuals with diabetes, impaired glucose tolerance, and even normal individuals post
glucose intake suffer from impaired endothelium-dependent NO mediated vasorelaxation [11].
Endothelial dysfunction has been shown to possibly be linked with low levels of arginine as well
as a possible increased production of oxygen-derived free radicals that are likely associated with
repeated or prolonged bouts of postprandial hyperglycemia [10]. Kwano et al. (1999) found a
decreased association in brachial artery vasodilation with increased plasma levels of
thiobarbituric acid reactive substances (TBARS) that parallel the plasms glucose levels in the
respective groups, while serum nitrite/nitrate levels remained the same post glucose loading [10].
Diseases that cause impaired endothelial function and increase reactive oxygen species (ROS)
such as atherosclerosis and diabetes, have been shown to cause eNOS uncoupling, which causes
eNOS to produce the oxygen-derived free radical superoxide instead of NO which lead to a
reduction in eNOS activity [27, 21]. During periods of high oxidative stress, superoxide is
produced. Superoxide then reacts with NO to produce peroxynitrite. The production of
peroxynitrite leads to the oxidation of tetrahydrobiopterin (BH4) into BH2 which cannot be
recycled back into BH4, causing the uncoupling of eNOS and reducing oxygen to superoxide and
diminishing the synthesis of NO [28]. In healthy individuals, BH4 maintains the function of
eNOS by being oxidized into trihydropterin radicals (BH3H+) which are then recycled into BH4
by reduction [28].
1.5 Flow-Mediated Dilation and Near-Infrared Spectroscopy
Changes in the vascular and endothelial tissues are best measured by using flow-mediated
dilation (FMD) of the brachial artery. Near-infrared spectroscopy (NIRS) is another method to
measure microvascular responses post-ischemia and can be used in conjunction with FMD.
5

FMD and NIRS have been used in conjunction to measure the vascular and microvascular
response to hyperglycemia. FMD is a non-invasive measure believed to reflect endotheliumdependent NO-mediated arterial function and vascular health [41]. NIRS has been proven to be
a valid measure to detect changes in oxidative metabolism as well as microvascular
responsiveness during an oral glucose challenge [42, 43]. FMD and NIRS have recently been
used in conjunction to support the relationship of down (brachial artery FMD) and upstream
(forearm NIRS) vascular reactivity [44, 45, 46]. Soares et al. (2019) showed a significant
correlation (r=0.66; P = 0.001) between the NIRS reperfusion slope and FMD % in healthy
active individuals [44].
1.6 Type 2 Diabetes
T2D involves many complications with the vascular and endothelial systems. Vascular
disease, which originates from endothelial dysfunction, is the primary cause of morbidity and
mortality in individuals with T2D [34, 35, 36]. Insulin-stimulated NO production via increasing
NOS stimulation, thus insulin-resistant individuals have a reduced NO-mediated vasodilatory
response [48]. Individuals with T2D have diminished endothelium-derived vasodilatory in
response to NO as well as impairments to the sympathetic nervous system compounding further
vascular dysfunction [48]. Endothelial dysfunction is likely due to chronic hyperglycemia, the
eNOS inhibitor asymmetric dimethylarginine (ADMA), and ROS in individuals with T2D.
Chronically elevated glucose levels can inactivate the NOS cofactors located in the kidney and
endothelium, causing NOS uncoupling and therefore reductions in citrulline concentrations [37,
38]. Individuals with T2D typically have elevated circulating free fatty acid levels. The elevated
levels of free fatty acids activate lipoprotein lipase to metabolize the high levels of free fatty
acids circulating and decrease insulin sensitivity. The elevated levels of circulating free fatty
6

acids could be a contributing factor to reduced NOS activity thus a decreased NO bioavailability
in insulin-resistant individuals [48].
1.7 Hyperglycemia
Postprandial hyperglycemia in which the vascular recovery of the endothelium is
compromised after ingesting glucose or a mixed meal has been shown to contribute to CVD.
Recent evidence demonstrates that acute or postprandial hyperglycemia shows impairments in
vascular function of individuals with a history of vascular endothelial dysfunction as well as
healthy individuals [8, 9, 10, 29]. The severity of postprandial hyperglycemia has been shown to
be a better predictor of future CVD mortality compared with fasting glucose in both diabetic and
normal individuals [8]. Numerous other studies have observed a graded relationship between
increasing fasting or postprandial glucose levels and the risk of cardiovascular events in
nondiabetic populations [9]. Kawano et al. (1999) showed that glucose loading suppresses
endothelium-dependent vasodilation in healthy individuals as well as impaired glucose tolerance
groups, measured by FMD [10]. This decrease in FMD could be due to decreases in NO
synthesis, increased uncoupling of eNOS, and/or greater consumption of NO by reactive oxygen
species [10]. Oxidative stress induced by hyperglycemia decreases the activity of
dimethylarginine dimethylaminohydrolase (DDHA) which degrades ADMA, whose role is to
inhibit eNOS (19). Higher levels of ADMA relative to arginine have been related to an
increased CVD risk by decreasing the biosynthesis of NO due to inhibiting the binding of
arginine to eNOS (19). Acute hyperglycemia induces lipid peroxidation and increases ADMA:
arginine independent of any changes in inflammation leading to the suppressed vascular function
(18).
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Endothelial dysfunction has been linked to individuals with diabetes as well as
individuals with chronic hyperglycemia which are often seen as the cause of endothelial function
[10]. These diseases contribute to abnormalities in the vascular and smooth muscle cells
contributing to vascular disease. Since eNOS is constitutively active, the bioavailability of NO is
considered a marker of vascular health. The uncoupling of eNOS is thought to be a major
contributor to the endothelial dysfunction associated with aging, cardiometabolic disease, and
menopause. The bioavailability of NO is a reflection of the balance between its production from
NOS and its degradation, particularly by the ROS superoxide [11].
NADPH oxidases transfer electrons across biological membranes, with oxygen often
being the acceptor of the electron [47]. The free radical superoxide has been shown to react with
NO to produce peroxynitrite which decreases NO bioavailability [21]. NO and superoxide have
opposite effects on the vasculature. NADPH-dependent ROS generation causes the depletion of
NO and promotes the uncoupling of NOS [47]. This NOX activation leads to an increased
production of superoxide leading to a breakdown of NO [47]. Notably, this relationship between
NO and NADPH derived superoxide act as a reversible signaling mechanism [47]. Furthermore,
superoxide can be removed by superoxide dismutase to reduce the breakdown of NO [49].
Citrulline has been shown to increase levels of arginine, nitrate/nitrite (NOx), and cGMP
activities after citrulline supplementation in healthy young adults [3, 12]. While other studies
have seen similar increases in arginine availability and increased urinary NOx levels, endothelial
function is measured by brachial artery FMD, but acute supplementation with citrulline (~7 days)
did not show an increase in FMD [3, 13].
Acute (~7 days) citrulline supplementation has shown an increase in exercise
performance and prolongs time to fatigue in mice [17]. In humans, acute ingestion (6g/day for
8

14 days) of citrulline has shown a significant increase to blood flow and plasma arginine levels
in older men and women despite not showing an increase in NOx during exercise [14]. Other
studies have shown an increase in endurance exercise performance with citrulline
supplementation, including an increase in plasma nitrate-nitrite for both the citrulline (21%) and
arginine (28%) groups. This increase in plasma nitrate-nitrite in both groups, despite the
significantly improved tissue oxygen index and power outputs for the citrulline group, put into
question to what extent does plasma nitrate-nitrite reflect skeletal muscle NOS activity (12).
To summarize, vascular and endothelial function plays a pivotal role in the health and
wellbeing of individuals with NO and its bioavailability at the foundation. There is strong
evidence that oral consumption of watermelon juice could be beneficial in attenuating the
decrement seen in endothelial function during hyperglycemia.
1.8 Purpose
The purpose of this pilot study is to determine the potential for citrulline-rich watermelon
juice to attenuate the reduction in postprandial endothelial function associated with reduced
skeletal muscle microvascular blood flow (MVBF) during hyperglycemia. We hypothesize that
the watermelon juice supplementation will attenuate the reduction in endothelial dysfunction and
microvascular blood flow during an oral glucose challenge. We also hypothesize that
watermelon juice will increase L-arginine bioavailability during hyperglycemia and correlate
with improved vascular response.
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Chapter 2. Methods
2.1 Participants
Seventeen participants (5 Male, 12 Females) were recruited through word of mouth and
flyers from the LSU campus. Participants were healthy males and females 18 – 40 years of age
with a BMI between 18-29.9 kg/m2. Participants were excluded if they or a first-degree relative
had type 1 or 2 diabetes, were an active smoker, allergic to watermelon, have a history of
vascular disorders, on any known medication that could influence the study outcomes, or taking
supplements including arginine, citrulline, or beta-alanine.
Participants interested in participation filled out a health screening, PAR-Q, as well as the
informed consent for the study. After these documents were reviewed, if particpants met all of
the inclusion/exclusion criteria, they were scheduled for a screening visit then a follow-up OGTT
visit. The study was a double blinded, randomized, counterbalanced design.
2.2 Screening Visit
During the screening visit, participants were required to come in fasted from food and
drink (except water) for at least 10 hours, 48-72 hours without alcohol or strenuous exercise. A
fasting baseline blood draw was taken to measure glucose, lipids, and CBC. Then participants
had body composition measured by dual x-ray absorptiometry (DXA). Women were required to
take a pregnancy test before the DXA. Participants were briefed on the risks of the DXA, then
prepared by removing all metal and shoes for the full-body scan. Once the DXA was completed
the participants were randomized and put into contact with the distributor at the LSU AG Center
to schedule out their visits for receiving the supplement or placebo.
2.3 Supplement Visits
10

Participants were required to have a minimum of 10 and a maximum of 17 doses of
supplementation (average 12.8, 10-16 days). The participants were asked to receive the juice or
placebo from the food science laboratory at LSU Agricultural Center where they would take one
dose per day. On weekends participants were provided with two doses of juice or placebo to
account for the closure of the AG Center. Participants were also provided with juice or placebo
for anticipated instances where they could not make it to the AG Center. Both the participants as
well as the researchers administering the OGTT were blinded to the supplementation.
2.4 Washout Period
Before starting phase 2 of supplementation, the participants were required to wash out a
minimum of 14 days following the day of the OGTT. Immediately before the initiation of phase
2, participants underwent a post-washout fasted blood draw. Following the blood draw, the
participant would be again put into contact with the AG Center and start receiving the condition
they did not receive prior.
2.5 Visit 2 & 3: Oral Glucose Tolerance Test – Postprandial FMD and MVBF
Participants arrived in the morning fasted from food and drink (except water) for at least
10 hours, 48-72 hours without alcohol or strenuous exercise. Body composition was measured
by DXA and pregnancy test was administered for females before testing. Next, participants
rested for 30 minutes in the supine position while wearing a heart rate monitor (Zephyr,
Bioharness) to measure heart rate and heart rate variability. Resting metabolic rate was
measured via indirect calorimetry for 20 minutes. MVBF (near-infrared spectroscopy) was
measured for 3 rounds of 10 seconds on 2 minutes off then brachial artery FMD (ultrasound) was
taken following a 5-minute occlusion. An intravenous catheter was inserted in the patient's left
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arm and a baseline blood sample was taken. The participant then had 5 minutes to drink the 75gram glucose solution, once the participant was finished, a timer was started. Blood was drawn
from the IV at 15, 30, 60, 90, and 120 minutes post glucose ingestion. Postprandial
measurements of FMD and MVBF were taken at 30, 60, and 90 minutes post glucose ingestion.
2.6 Flow-Mediated Dilation
FMD measurements were taken according to the standard procedures supported by the
American Heart Association [40]. With permission from the participant, A blood pressure cuff
(Delphi) was placed on the upper forearm distal to the ultrasound probe and proximal to the
NIRS optodes. The participant was asked to stay still through the duration of the measurement
with their right arm out at 80 degrees and supinated. The brachial artery of the right arm was
identified using color and Doppler modes and scanned using B-mode on the ultrasound
(Hologic). Following at least 2 minutes post microvascular occlusion, baseline images were
recorded of the brachial artery pre-occlusion. Each image attained was ~17 seconds in duration.
The ultrasound probe was held in place by using an ultrasound adjustable clamp (QUIPU, Italy)
to ensure image quality and reproducibility. The cuff was inflated using a rapid cuff inflation
system (Hokanson E20, Bellevue WA) controlled using a custom-built control system Labview
Software algorithms (developed by Pedro J Chacon Dominguez, Jin-Woo Choi, and Brian A
Irving). Inflation was continuous at 250mmHg for 5 minutes. Before the release of cuff
inflation, the participant was reminded to remain still and videos of the brachial artery were
attained immediately post-deflation, 1, 3, and 5 minutes post deflation. FMD videos were
analyzed by Brachial Analyzer for research software (mia-llc, Coralville, Iowa). Then FMD was
measured using the following equation:
𝐹𝑀𝐷 = (𝑃𝑒𝑎𝑘 𝑑𝑖𝑎𝑚𝑒𝑡𝑒𝑟 – 𝐵𝑎𝑠𝑒𝑙𝑖𝑛𝑒 𝑑𝑖𝑎𝑚𝑒𝑡𝑒𝑟) ÷ 𝐵𝑎𝑠𝑒𝑙𝑖𝑛𝑒 𝑑𝑖𝑎𝑚𝑒𝑡𝑒𝑟
12

2.7 Microvascular Blood Flow-Near Infrared Spectroscopy (NIRS)
The NIRS system was calibrated prior to the subject arrived for each visit. The NIRS
optodes (Oxymon MKIII, Artinis Medical Systems) were placed longitudinally on the flexor
digitalis superficialis (forearm) and measured to ensure reproducibility. The optodes were
secured in place with two-sided adhesive tape and further anchored in place with additional
medical tape. The rapid inflation cuff was placed proximal to the optodes. After ensuring
correct probe placement the participants laid their supine at 80 degrees and were instructed to
remain still for the course of the measurements. The cuff was rapidly inflated to 60mmHg for 10
seconds and rapidly deflated for 2 minutes for 3 rounds. NIRS signals for oxygenated
(O2Hb/O2Mb), deoxygenated (HHb/HMb), total (tHb/tMb) hemoglobin/myoglobin, and tissue
O2 Saturation (TSI) (%) were continuously monitored through the MVBF as well as FMD.
The microvascular blood flow response was measured by calculating the slope of the
linear increase total hemoglobin (tHb): BF= (((DtHb x 60)/ ((([Hb] x1000)/4))x1000/10 in ml-1
•min•100ml-1. Baseline TSI was calculated from the 2 minutes prior to ischemic occlusion. The
ischemic-reperfusion slope was calculated from the slope of linear increase at the point of cuff
release to 10-seconds post-reperfusion.
Paired t-test and repeated measures and mixed mold two-way ANOVA were utilized to
analyze data where appropriate (Prism, Graphpad). Main effects were defined as “time”
(between individual time points within a visit) and “treatment” (PLA vs. WMJ). Multiple
comparisons were made by Holm-Sidak’s test. Statistical significance was declared at P<0.05.
All data were reported as mean ±SEM. Calculations of the incremental area under the curve
(AUC) were made by the trapezoidal method.
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Chapter 3. Results
3.1 Participant Characteristics
All individuals were non-obese (%Fat Mass= 27.72±7.89%), young adults (Age= 23±3y),
with normal or overweight BMI (BMI= 23.48±3.22kg/m2) with 17 total participants (12 female,
5 male). Two of the female participants completed only 1 of the visits and were removed from
repeated measures analysis. The participant characteristics did not differ from baseline to their
last visit as shown in Table 1. The average time of supplementation for WMJ trial supplemented
was 13 days (Range 10-15) and the average time for the placebo was 13 days (Range: 10-16).
The washout period lasted for 16 days (Range: 14-21) days. Due to technical issues with the
production of the WMJ supplement, the first 5 participants were given WMJ in the first trial, the
following 5 participants were given PLA as the first trial to match this, then the remaining
participants were randomized to the order of their trials. However, the double-blinded, crossover, counterbalanced nature of the study design was maintained throughout the study.
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3.2 Oral Glucose Tolerance Test
Participants baseline blood glucose concentrations increased from (5.20±0.37 mmol·L-1)
at baseline to (6.73±0.93 mmol·L-1) at 15 minutes and peaking at (8.06±1.38 mmol·L-1) at 30
minutes, then (7.52±2.10 mmol·L-1) at 60 minutes, to (6.10±1.52 mmol·L-1) at 90 and finally
(5.53±1.60) at 120 minutes post glucose ingestion. Figure 1 depicts a significant time effect in
glucose levels (p=<0.0001) with no significant treatment (p=0.18) or treatment by time effect
(p=0.74) in WMJ or PLA groups. Glucose AUC was not significant throughout the trail
(p=0.43). RER at baseline was 0.787 then 0.841 at 60 minutes and 0.826 at 120 minutes post
glucose ingestion with a significant time effect (p<0.0001) with no treatment effect (p=0.46).
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3.3 Flow-Mediated Dilation
Table 2 displays the baseline and peak brachial artery diameter at 0 (pre glucose
ingestion) 30, 60, and 90 minutes following the oral glucose ingestion. Figure 2b depicts the
percent change in FMD between WMJ and PLA groups following the oral glucose challenge
with a significant treatment effect (p=0.038). Percent change in 60-second post occlusion FMD
has a time effect trending towards significance (p=0.057) in the WMJ group demonstrated in
Figure 2a. A higher percentage of participants demonstrated a longer time to peak artery
diameter at 30 minutes post glucose ingestion represented in Figure 3.

16
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3.4 Near-Infrared Spectroscopy
At 30 minutes post glucose ingestion, plasma glucose increases while oxygen saturation
(StO2) decreases in both WMJ and PLA groups as shown in Figure 4. Baseline StO2 (average
StO2 180 seconds prior to cuff occlusion) was significantly higher in WMJ vs PLA (p=0.031)
and the baseline StO2 area under the curve (AUC) was significantly greater in WMJ vs PLA
(p=0.03) as depicted in Figure 5. Hyperglycemia has been cited to reduce microvascular
endothelial function [54]. Slope 2 (reperfusion slope) is inversely correlated with plasma glucose
(R2=0.17; p=0.0002) depicted in Figure 6. Figure 7 displays a significant time effect (p=0.03)
and time by treatment effect trending towards significance (p=0.072) in WMJ vs PLA
18

reperfusion slope. Reperfusion AUC (8-minute) shows a significant time effect (p<0.0001) and
trends towards a significant treatment effect (p=0.13) as displayed in Figure 8a. The mean
reperfusion AUC (8-minute) trends towards a significant increase in WMJ vs PLA group
(p=0.086) as exhibited in Figure 8b. Figure 9 depicts the microvascular blood flow from 0minute (pre-glucose) to 90 minutes post glucose ingestion showing a significant time effect
(p=0.023) with no significant treatment effect. No significant differences were observed in mean
blood flow or baseline blood flow in WMJ vs PLA despite baseline blood flow trending toward
significance (p=0.15) as exhibited in Figure 10.
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Chapter 4. Discussion
4.1 Hyperglycemia and Vascular Function
Diseases such as T2D, hypertension, obesity, and CVD all negatively impact health on a
global scale. The decrement in quality of life caused by these diseases has been linked to
diminished vascular-endothelial function. Hyperglycemia has been shown to cause a reduction
in blood flow and vascular responsiveness [8, 43, 51]. We sought to attenuate the reduced
endothelial response to postprandial hyperglycemia via supplementation with WMJ which has
shown to have promising endothelial effects.
4.2 Oral Glucose Tolerance Test
A 75-gram glucose OGTT was administered to induce a hyperglycemic response which
has been shown to increase plasma glucose levels rapidly causing vascular resistance despite the
following increase in plasma insulin. Glucose was elevated as expected and peak glucose
occurred at the 30-minute time and stayed elevated at 60 minutes in accordance with similar
trials in healthy individuals [8,43]. WMJ groups showed no significant differences in
hyperglycemia indicating changes in FMD or NIRS were not derived from differences in plasma
glucose.
4.3 Flow-Mediated Dilation
We expected to see decrements in FMD% when plasma glucose was at peak indicating
the attenuated endothelial response caused by hyperglycemia in response to an OGTT as shown
by Russell et al [51]. The change in vessel diameter (FMD%) was assessed at 60 seconds, 180
seconds, and 300 seconds after cuff release. Peak vessel diameter change was reduced 30minutes post glucose ingestion. Mah et al. reported a similar decrement in FMD but at 60
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minutes post glucose ingestion, this could be due to our population including healthy females
and males as opposed to solely males [18]. Black et al (2005) reported 58% of peak FMD%
were found from 50-70 seconds post cuff release in healthy young individuals [52]. Conversely,
80% of our participants reached peak FMD% at 60 seconds at baseline, but 30 minutes following
glucose ingestion the time to peak FMD% increased then recovers similar to baseline. This is
likely attributed to the peak in glucose occurring at the same time followed by the vasodilatory
response of insulin in the later time points. This interaction could also be linked to peak glucose,
further attenuating vasoresponsiveness during hyperglycemia. Baseline FMD% significantly
increased with the supplementation of WMJ when compared to PLA. This response can likely
be attributed to the prolonged supplementation of citrulline leading to increased NO
bioavailability. In conjunction with FMD, the NIRS data also exhibited similar promising
trends.
4.4 Near-Infrared Spectroscopy
Following the trends with FMD, we observed a decrease in baseline StO2 at 30 minutes
in both groups where peak glucose occurred. In the WMJ group, there was a trend toward a
significant treatment effect (p=0.11) as well as a significant time effect (p=0.03) when compared
to the placebo. The observed improvement in baseline StO2 suggests WMJ attenuates the
reduction of endothelial function observed during hyperglycemia. Supplementing with WMJ
significantly increased baseline StO2 AUC which is likely related to improved chronic
endothelium function. Soares et al. (2017) noted a linear significant increase in slope 2
(reperfusion slope) at 90 minutes post glucose ingestion, however, they did not measure insulin
which is a major vasodilator [43]. In our hands, we noted a similar trend in PLA peak slope 2 at
60 minutes, whereas the WMJ group demonstrated peak slope 2 at 30 minutes post glucose
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ingestion, despite having a significant time effect (p=0.043). McLay et al (2016) suggest that
slope 2 is a more repeatable measure of vascular responsiveness than FMD% [53]. We observed
a significant inverse relationship (p=0.0002) in glucose and slope 2 displaying that
hyperglycemia impairs skeletal muscle reperfusion. There was no correlation between
reperfusion AUC (8-minute) and slope 2 whereas Soars et al (2017) reported an inverse
relationship between the two [43]. We did not detect a significant treatment effect for the
reperfusion AUC (8-minute) despite a trend toward improvement with WMJ (p=0.13).
Likewise, the mean reperfusion AUC (8-minute) was also nearly significant (p=0.08). It is
reasonable to speculate that WMJ supplementation improves the vascular environment during
hyperglycemia based on the sustain higher StO2 and trend towards improved vascular
reperfusion. In T2D as well as hyperglycemia microvascular blood flow is significantly reduced
[9,10,18,51]. We observed a significant time effect (p=0.023) in microvasculature blood flow
with a reduction in blood flow at peak glucose. Baseline microvasculature blood flow trends
towards significance in the WMJ group
4.5 Limitations
This study was designed to investigate upstream and downstream vascular responsiveness
to 2 weeks of WMJ supplementation shown to provide an additional 3g of Citrulline compared to
supplementation with a placebo designed to taste similar to the WMJ. Technical limitations
prevented the assessment of simultaneous pulse wave velocity with a high-quality B mode video.
Instead, we used NIRS to measure microvascular blood flow. Cardiovascular fitness is a major
predictor of endothelial function and vascular health. We did require a physical activity
questionnaire and asked participants to abstain from exercise prior to study visits, general
physical activity was not accounted for. Last, we cannot confirm the pancreatic responsiveness
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to the OGTT with insulin or determine the effectiveness of the WMJ supplementation to raise Lcitrulline levels. However, in the future, we will use archival samples from this study to measure
serum insulin and L-citrulline levels. At the present time, we do not have serum insulin or
circulation markers of NO activity (Nitrate) these analyses will be run in the future.
4.6 Considerations for Future Research
Future research could investigate at a combination supplement of citrulline, arginine, and
nitrates in conjunction to possibly elicit a more robust response. The data from this study give
merit for a similar study in individuals with decreased vascular responsiveness such as T2D or
family history of T2D.
4.7 Conclusion
The main finding of this study confirms the previously reported relationship between
hyperglycemia and decreased skeletal muscle microvascular function. We also confirmed
decreased endothelial function, in a healthy-young population, during an OGTT. The purpose of
this study was to determine the effect of WMJ supplementation on endothelial function and
skeletal muscle microvascular function during experimental hyperglycemia. We demonstrated
WMJ supplementation is an effective method for improving vascular responsiveness during
hyperglycemia via improved baseline oxygen saturation and improved baseline FMD.
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